Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARSCoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.
Errataetall: | |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
---|---|
Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 09. Juni |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Schmidt, Fabian [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 11.02.2024 published: Electronic UpdateIn: J Exp Med. 2020 Nov 2;217(11):. - PMID 32692348 Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1101/2020.06.08.140871 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM311561179 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM311561179 | ||
003 | DE-627 | ||
005 | 20240211231830.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2020.06.08.140871 |2 doi | |
028 | 5 | 2 | |a pubmed24n1288.xml |
035 | |a (DE-627)NLM311561179 | ||
035 | |a (NLM)32577658 | ||
035 | |a (PII)2020.06.08.140871 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Schmidt, Fabian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 11.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a UpdateIn: J Exp Med. 2020 Nov 2;217(11):. - PMID 32692348 | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARSCoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1) and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies | ||
650 | 4 | |a Preprint | |
700 | 1 | |a Weisblum, Yiska |e verfasserin |4 aut | |
700 | 1 | |a Muecksch, Frauke |e verfasserin |4 aut | |
700 | 1 | |a Hoffmann, Hans-Heinrich |e verfasserin |4 aut | |
700 | 1 | |a Michailidis, Eleftherios |e verfasserin |4 aut | |
700 | 1 | |a Lorenzi, Julio C C |e verfasserin |4 aut | |
700 | 1 | |a Mendoza, Pilar |e verfasserin |4 aut | |
700 | 1 | |a Rutkowska, Magdalena |e verfasserin |4 aut | |
700 | 1 | |a Bednarski, Eva |e verfasserin |4 aut | |
700 | 1 | |a Gaebler, Christian |e verfasserin |4 aut | |
700 | 1 | |a Agudelo, Marianna |e verfasserin |4 aut | |
700 | 1 | |a Cho, Alice |e verfasserin |4 aut | |
700 | 1 | |a Wang, Zijun |e verfasserin |4 aut | |
700 | 1 | |a Gazumyan, Anna |e verfasserin |4 aut | |
700 | 1 | |a Cipolla, Melissa |e verfasserin |4 aut | |
700 | 1 | |a Caskey, Marina |e verfasserin |4 aut | |
700 | 1 | |a Robbiani, Davide F |e verfasserin |4 aut | |
700 | 1 | |a Nussenzweig, Michel C |e verfasserin |4 aut | |
700 | 1 | |a Rice, Charles M |e verfasserin |4 aut | |
700 | 1 | |a Hatziioannou, Theodora |e verfasserin |4 aut | |
700 | 1 | |a Bieniasz, Paul D |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 09. Juni |w (DE-627)NLM31090014X |7 nnns |
773 | 1 | 8 | |g year:2020 |g day:09 |g month:06 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.06.08.140871 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2020 |b 09 |c 06 |